Assay Detail
Binding
CHEMBL4766286
Review assay metadata, readout intent, target linkage, and publication context from the same page.
Inhibition of human ERG
4
Total Activities
4
Compounds Tested
2
Activity Types
0
Assay Parameters
Assay Information
| Assay Type | Binding |
| Organism | Homo sapiens |
| Confidence | 9 — Direct single protein target |
| Curated By | Autocuration |
Target
Voltage-gated inwardly rectifying potassium channel KCNH2 (CHEMBL240) ↗| Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
Publication
The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
Activity Statistics
| Type | Count | Avg pChEMBL | Best pChEMBL |
|---|---|---|---|
| IC50 | 3 | - | - |
| Ki | 1 | 5.20 | 5.20 |
Compounds Tested
| Compound | Name | Phase | Activities | Best pChEMBL |
|---|---|---|---|---|
| CHEMBL4781604 | — | — | 1 | 5.20 |
| CHEMBL3915620 | LY2881835 | 1.0 | 1 | - |
| CHEMBL4787498 | — | — | 1 | - |
| CHEMBL3955132 | — | — | 1 | - |
Activity Data
| Compound | Name | Type | Rel. | Value | Units | pChEMBL |
|---|---|---|---|---|---|---|
| CHEMBL4781604 | — | Ki | = | 6300.0 | nM | 5.20 |
| CHEMBL3915620 | LY2881835 | IC50 | > | 10000.0 | nM | - |
| CHEMBL4787498 | — | IC50 | > | 10000.0 | nM | - |
| CHEMBL3955132 | — | IC50 | > | 10000.0 | nM | - |